These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17459739)

  • 1. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.
    Buyse GM; Goemans N; Henricson E; Jara A; van den Hauwe M; Leshner R; Florence JM; Mayhew JE; Escolar DM
    Eur J Paediatr Neurol; 2007 Nov; 11(6):337-40. PubMed ID: 17459739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
    Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
    Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
    Mayhew JE; Florence JM; Mayhew TP; Henricson EK; Leshner RT; McCarter RJ; Escolar DM
    Muscle Nerve; 2007 Jan; 35(1):36-42. PubMed ID: 16969838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prednisone treatment in Duchenne muscular dystrophy.
    Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
    Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy.
    Daftary AS; Crisanti M; Kalra M; Wong B; Amin R
    Pediatrics; 2007 Feb; 119(2):e320-4. PubMed ID: 17272595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.
    Spurney CF; Rocha CT; Henricson E; Florence J; Mayhew J; Gorni K; Pasquali L; Pestronk A; Martin GR; Hu F; Nie L; Connolly AM; Escolar DM;
    Muscle Nerve; 2011 Aug; 44(2):174-8. PubMed ID: 21698649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial manual muscle testing in Duchenne muscular dystrophy.
    Kilmer DD; Abresch RT; Fowler WM
    Arch Phys Med Rehabil; 1993 Nov; 74(11):1168-71. PubMed ID: 8239956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisolone in Duchenne muscular dystrophy.
    Rahman MM; Hannan MA; Mondol BA; Bhoumick NB; Haque A
    Bangladesh Med Res Counc Bull; 2001 Apr; 27(1):38-42. PubMed ID: 11692899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].
    Desnuelle C; Serratrice G; N'guyen VK; Richelme C; Pinsard N
    Arch Fr Pediatr; 1989 Dec; 46(10):759-65. PubMed ID: 2697199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
    Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
    Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.
    Zimmerman A; Clemens PR; Tesi-Rocha C; Connolly A; Iannaccone ST; Kuntz N; Arrieta A; Hache L; Henricson E; Hu F; Mayhew J; Escolar DM
    Muscle Nerve; 2011 Aug; 44(2):170-3. PubMed ID: 21674534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.
    Söderpalm AC; Magnusson P; Ahlander AC; Karlsson J; Kroksmark AK; Tulinius M; Swolin-Eide D
    Neuromuscul Disord; 2007 Dec; 17(11-12):919-28. PubMed ID: 17627820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation.
    Desguerre I; Mayer M; Leturcq F; Barbet JP; Gherardi RK; Christov C
    J Neuropathol Exp Neurol; 2009 Jul; 68(7):762-73. PubMed ID: 19535995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy.
    Fenichel GM; Griggs RC; Kissel J; Kramer TI; Mendell JR; Moxley RT; Pestronk A; Sheng K; Florence J; King WM; Pandya S; Robison VD; Wang H
    Neurology; 2001 Apr; 56(8):1075-9. PubMed ID: 11320181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial.
    Payan CA; Hogrel JY; Hammouda EH; Lacomblez L; Ollivier G; Doppler V; Eymard B; Attarian S; Pouget J; Desnuelle C; Laforêt P
    Arch Phys Med Rehabil; 2009 Jul; 90(7):1094-101. PubMed ID: 19577021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.